I went to try and find where Gilles talked about the net present value of the potential PGX immune booster facility to try and nail down what was said. This is from almost three years ago. He said $100 million net present value using a 20% discount rate assumed 3% market share in this presentation @ 21:50:
Ceapro (CRPOF) CEO Gilles Gagnon – Presentation from NobleCon17 (yo utube.com)
If the 10X scale-up works out and the animal trial and they're convinced they have the gold standard perhaps a plant configured for greater than 3% market share would be constructed.
A news release around the time of the video talked about Germany being the ideal spot for a location:
"...it became clear that location of the first large scale PGX unit should be close to the best source of raw material which was found in Germany where the Company also acquired pieces of equipment suitable for the assembling of such unit." April 22, 2021 news release
Gilles said in his October presentation they were collaboaating with Kerry and Leiber. Leiber is in Germany and now with the proposed AEZS merger AEZS also has a German footprint. Maybe CZO can have a German facility for the European market and Canadian facility for the North American market.